Single-Use Pump Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Global Single-Use Pump Market Trends and Insights

Rising Adoption of Single-Use Bioprocessing in Biologics Manufacturing

Global biologics producers are replacing stainless-steel infrastructure with disposable platforms to turn over batches faster and trim capital risk. Fujifilm Diosynth allocated USD 1.6 billion in 2024 for eight 20,000 L single-use bioreactors that double its capacity and remove weeks of cleaning downtime^{[1]Fujifilm Diosynth Biotechnologies, “Company Announces USD 1.6 Billion Investment,” fujifilmdiosynth.com}. Lotte Biologics earmarked USD 1 billion to reach top-ten CDMO status by relying on fully disposable suites that allow multi-product changeovers within hours. Although consumables raise per-batch costs by 25-29%, the saved validation time accelerates new therapy launches, outweighing expense concerns. Samsung Biologics and SK pharmteco jointly invested USD 260 million in Korea to standardize single-use layouts, signalling this model as the mainstream for new greenfield plants.

Technological Advances in Low-Shear Peristaltic & Diaphragm Designs

Pump makers are engineering gentle fluid paths to prevent protein aggregation during circulation. Watson-Marlow’s Quantum pump pairs ReNu SU cartridges with precise servo control to transport sensitive monoclonal antibodies under minimal shear. Magnetic-bearing devices from Levitronix remove mechanical contact altogether, eliminating friction and extending cartridge life. Conveying Wave Technology (CWT) moves fluids through an oscillating chamber, delivering ±1% dosing accuracy while reducing chemical exposure by 97.5%^{[2]Spirax-Sarco, “Watson-Marlow Fluid Technology Solutions,” spiraxgroup.com}. Such innovations underpin reliable scale-up for cell and gene therapies where product loss is costly.

Growing Chronic-Disease Prevalence Spurring Demand for Advanced Therapies

Rising incidence of cancer, autoimmune conditions, and rare genetic disorders intensifies the pipeline of complex biologics, driving upstream and downstream volumes that single-use pump market vendors aim to serve. Precision drugs often require small, high-value batches processed under stringent sterility. Disposable pumping lines minimise cross-contact risk when manufacturers alternate between niche therapies. Health-system pressure to shorten development timelines further tilts decisions toward ready-to-install skids that align with accelerated approval pathways.

Expansion of CDMO Capacity for Rapid Scale-Up

CDMOs race to offer turnkey production to sponsors lacking internal infrastructure. CordenPharma’s EUR 900 million peptide build-out and Terumo’s multiproduct expansion highlight demand for platforms that adapt to shifting molecule portfolios. Global single-use pump market suppliers benefit as contract sites prefer standardised, vendor-qualified cartridges that meet diverging client protocols. BioProcess International estimates 16.5 million litres of global bioprocess capacity in 2025, with China and India adding the largest shares to pursue Western outsourcing contracts. This capacity wave anchors steady pump sales across facility lifecycles.

Limited Suitability in High-Pressure Downstream Filtration

Ultrafiltration and diafiltration steps for high-concentration monoclonal antibodies run above 3 bar, exceeding safety margins for many disposable casings. The United States FDA emphasises precise pressure control during sterile filtration, adding validation hurdles when polymer integrity is uncertain^{[3]US FDA, “Essential Drug Delivery Outputs Guidance,” fda.gov}. Hybrid facilities often pair single-use lines upstream with stainless-steel skids downstream, diluting the simplicity advantage that motivates disposable adoption. Intensifying demand for high-viscosity formulations suitable for subcutaneous delivery compounds the pressure challenge, as pumps must maintain accuracy despite rising fluid resistance.

Regulatory Scrutiny on Plastic Waste & PFAS Leachables

European PFAS proposals threaten fluoropolymer supply chains that underpin high-performance liners. Saint-Gobain shifted its PharmaFluor FEP tubing to non-fluorinated polymerisation aids, while Sartorius warned that future bans could extend to PVDF filters. The FDA’s 2024 draft rule elevates extractables and leachables testing, mandating full chemical profiles for every disposable component. Compliance raises certification lead-times and cost, encouraging conservative purchasing in green-minded regions. Vendors respond by investing in recyclable materials and closed-loop recovery programs, yet infrastructure remains nascent.

Segment Analysis

By Product: Equipment Dominance Drives Innovation

Equipment generated 66.51% revenue in 2024, reflecting the fundamental role of pumps at every bioprocess stage. Peristaltic units remain the cornerstone for aseptic fluid transfer, while quaternary diaphragm systems gain share in precision dosing for chromatography buffers. The single-use pump market size for equipment is projected to expand steadily as suppliers bundle hardware with sensing and control software. Accessories trail in absolute terms yet deliver the fastest 18.65% CAGR, fueled by batch-to-batch replacement of tubing, connectors, and pump cartridges. Leading vendors roll out integrated fluid-path kits, capturing lifecycle value after the initial skid sale.

Consumable revenue benefits from predictable procurement cycles embedded in current good manufacturing practice documentation. Watson-Marlow’s WMArchitect suite packages quick-fit manifolds and irradiation-ready tubing sets, enabling operators to achieve sub-15-minute changeovers. Niche firms focus on sterile weldable connectors and gamma-stable elastomers that address regulatory push for closed processing. Rising adoption of continuous bioprocessing further supports accessory volumes, as extended campaigns require periodic switch-out of wetted parts to uphold sterility within multiday runs.

By Flow Rate: Low-Flow Precision Meets High-Flow Scaling

Low-flow pumps dominated with 54.53% revenue in 2024, driven by cell and gene therapy protocols that mandate tight volumetric accuracy below 100 L/min. These systems safeguard fragile cells and reduce reagent waste during small-batch production. High-flow platforms are picking up momentum at a 15.85% CAGR, supported by expanding 5,000 L to 20,000 L single-use bioreactors in commercial monoclonal antibody plants. The single-use pump market size tied to high-flow tasks gains from escalating harvest volumes and perfusion strategies that circulate large media quantities daily.

Design divergence remains pronounced. Low-flow devices accentuate pulsation damping and pressure stability at sub-2 bar operation, whereas high-flow skids optimise motor torque and tubing wall strength to run continuous 24/7 campaigns. Modular stator assemblies enable manufacturers to calibrate identical drive units for distinct flow envelopes, lowering inventory costs. The rise of perfusion and continuous capture blurs historic cut-offs, prompting R&D toward pumps with variable-speed algorithms that auto-adjust to online biomass readings.

By Application: Downstream Processing Accelerates

Upstream steps retained 45.62% revenue in 2024 due to entrenched disposable bioreactor adoption and routine media transfers. Yet downstream operations post the leading 16.35% CAGR as producers tackle purification bottlenecks for high-titre biologics. Single-use chromatography skids, virus-filtration lines, and bulk-drug-substance fill systems embed pumps to drive constant flow through membranes and columns. The segment also benefits from process analytical technology frameworks pushing for closed, automated post-harvest phases.

Downstream growth hinges on cost-reduction imperatives: purification can represent more than half of total manufacturing expense for some recombinant proteins. Thermo Fisher’s purchase of Solventum’s filtration unit underscores strategic value in integrated single-use downstream suites. Pump vendors respond by incorporating low-hold-up volume manifolds and in-line pressure sensors that maintain uniform trans-membrane gradients, meeting regulatory expectations for consistent critical quality attributes.

By End-Use: CDMO Growth Reshapes Demand

Biopharmaceutical innovators and large pharma entities produced 62.25% of 2024 demand, prioritising validated, audit-ready hardware. However, single-use pump market demand from CROs and CMOs is growing at 16.55% CAGR, stemming from sponsor outsourcing and capacity constraints at originator firms. Contract operators standardise on versatile pump brands to flex across multiple client molecules without lengthy qualification loops.

Antylia Scientific’s evolution from Cole-Parmer reflects supplier pivot toward the CDMO customer base, emphasising rapid-delivery service and global cartridge availability. Academic sites remain smaller buyers yet act as proving grounds for cutting-edge formats such as disposable micro-pumps integrated into benchtop perfusion platforms. Increasing adoption of personalised medicine drives interest in single-use metering pumps capable of handling sub-litre batch volumes with pharmaceutical-grade accuracy.

Note: Segment shares of all individual segments available upon report purchase

By Material of Construction: Fluoropolymers Address Compatibility Challenges

Medical-grade polyethylene held 47.25% revenue in 2024 thanks to broad solvent tolerance and easy extrusion into tubing. Polypropylene satisfies elevated temperature cycles, while silicone elastomers secure peristaltic compression performance. Fluoropolymer liners, headed for an 18.25% CAGR, gain from unparalleled inertness that safeguards viral vector integrity and minimises extractables. Transition toward high-pH viral inactivation buffers and solvent-rich purification workflows bolsters demand for expanded polytetrafluoroethylene and perfluoroalkoxy resin coatings.

Regulatory scrutiny accelerates innovation in low-PFAS alternatives. Gore’s STA-PURE containers and Syensqo’s capacity expansion illustrate commitment to advanced barrier films compliant with tightening European thresholds. Simultaneously, resin shortages and logistic bottlenecks prompt dual-sourcing strategies, with OEMs qualifying redundant polymer grades to guarantee uninterrupted supply.

Geography Analysis

North America captured 37.75% of 2024 revenue on the strength of mature biomanufacturing clusters, well-defined regulatory guidance, and solid venture funding for advanced therapy pipelines. The FDA’s Quality Management System Regulation (QMSR) alignment with ISO 13485, effective 2026, streamlines cross-border device approvals and could accelerate new pump launches. Dover Corporation reported 7% organic growth in its pump division in Q1 2025, attributed largely to biopharma component shipments, highlighting resilient replacement demand. Research spending within the National Institutes of Health and Biomedical Advanced Research and Development Authority also supports pilot-scale installations across academic hubs.

Asia-Pacific is the fastest climber, advancing at a 15.45% CAGR toward 2030 as governments invest billions to achieve vaccine self-reliance and capture biologics outsourcing. Singapore’s state-backed mRNA vaccine push and South Korea’s USD 1.92 billion budget to become a top vaccine hub exemplify public-private collaboration. China and India expand Current Good Manufacturing Practice (CGMP) compliant capacity to serve multinational sponsors seeking cost-efficient production. Cytiva executives cite rapid growth in cell and gene therapy facilities enabled by fast-track regulatory channels in Australia, Japan, and Korea.

Europe commands a substantial share backed by stringent quality norms and deep biologics pipelines. Implementation of revised Good Manufacturing Practice Annex 1 in 2025 elevates sterility expectations, promoting wider uptake of disposable pumps that remove cleaning dead-legs. The European Shortages Monitoring Platform, mandatory from February 2025, incentivises flexible capacity capable of quick product switches, a core benefit of single-use. Regional suppliers however face input-cost volatility as resin pricing swings and PFAS legislation tightens, raising production-planning complexity.